Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials
Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.
/ 918 items
#Healthcare↓
FIGS Q3: Record Growth and Raised Outlook
FIGS, the healthcare apparel leader, announced exceptional Q3 2025 financial results, showing 8.2% revenue growth, improved profitability, and a boosted full-year outlook.
Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Wolfe Research Starts Coverage on Abivax with Outperform Rating and $176 Target
Wolfe Research initiates coverage of Abivax with an Outperform rating and $176 price target, citing strong potential for Crohn’s disease success and upcoming 2026 catalyst.
Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.
Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.